Basics Taysha Gene Therapies, Inc. IPO Date: September 24, 2020 Sector: Healthcare Industry: Biotech Market Cap: $1.38B Activated in VL: True Average Daily Range Avg Daily Range: $0.27 | 4.18% Avg Daily Range (30 D): $0.16 | 3.75% Avg Daily Range (90 D): $0.13 | 3.40% Institutional Daily Volume Avg Daily Volume: 1.55M Avg Daily Volume (30 D): 3.1M Avg Daily Volume (90 D): 4.62M Trade Size Avg Trade Size (Sh.): 203 Avg Trade Size (Sh.) (30 D): 142 Avg Trade Size (Sh.) (90 D): 188 Institutional Trades Total Inst.Trades: 456 Avg Inst. Trade: $1.87M Avg Inst. Trade (30 D): $1.45M Avg Inst. Trade (90 D): $1.67M Avg Inst. Trade Volume: .58M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.42M Avg Closing Trade (30 D): $1.7M Avg Closing Trade (90 D): $1.83M Avg Closing Volume: 683.6K     News Oct 17, 2025 @ 1:00 PM Sandhoff Disease Treatment Market Size Projects US... Source: Towards Healthcare Sep 5, 2025 @ 12:00 PM Taysha Gene Therapies Announces Inducement Grant U... Source: Hayleigh Collins Aug 1, 2025 @ 9:06 PM Taysha Gene Therapies Announces Inducement Grant U... Source: Hayleigh Collins Jun 3, 2025 @ 9:17 PM Taysha Gene Therapies Announces Details for Oral P... Source: N/A May 29, 2025 @ 2:40 AM Taysha Gene Therapies Announces Pricing of Public ... Source: N/A Financials   TTM Q3 2025 Q2 2025 Basic EPS $-.33 $-.09 $-.09 Diluted EPS $-.33 $-.09 $-.09 Revenue $ 6.31M $ M $ 1.99M Gross Profit $ $ $ Net Income / Loss $ -99.93M $ -32.73M $ -26.88M Operating Income / Loss $ -102.13M $ -34.02M $ -26.75M Cost of Revenue $ $ $ Net Cash Flow $ 139.66M $ -15.42M $ 196.17M PE Ratio